logo
Plus   Neg
Share
Email

Novartis: Ofatumumab Data Show Efficacy, Safety In Treatment Of Multiple Sclerosis

Novartis (NVS) announced new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial continue to demonstrate ofatumumab as a potential treatment option for patients with relapsing forms of multiple sclerosis. A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no evidence of disease activity (NEDA-3) within the first (0-12 months) and second year (12-24 months) of treatment, respectively. The safety profile was comparable to teriflunomide. Regulatory action for ofatumumab in the US is expected in June 2020.

Ofatumumab is a targeted B-cell therapy that, if approved, addresses a clinical unmet need as the first B-cell therapy that can be self-administered at home through an autoinjector pen.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT